Targeting SHIP1 and SHIP2 in Cancer
Membrane-anchored and soluble inositol phospholipid species are critical mediators of intracellular cell signaling cascades. Alterations in their normal production or degradation are implicated in the pathology of a number of disorders including cancer and pro-inflammatory conditions. The SH2-contai...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/4/890 |
| _version_ | 1797395881178169344 |
|---|---|
| author | Chiara Pedicone Shea T. Meyer John D. Chisholm William G. Kerr |
| author_facet | Chiara Pedicone Shea T. Meyer John D. Chisholm William G. Kerr |
| author_sort | Chiara Pedicone |
| collection | DOAJ |
| description | Membrane-anchored and soluble inositol phospholipid species are critical mediators of intracellular cell signaling cascades. Alterations in their normal production or degradation are implicated in the pathology of a number of disorders including cancer and pro-inflammatory conditions. The SH2-containing 5′ inositol phosphatases, SHIP1 and SHIP2, play a fundamental role in these processes by depleting PI(3,4,5)P<sub>3</sub>, but also by producing PI(3,4)P<sub>2</sub> at the inner leaflet of the plasma membrane. With the intent of targeting SHIP1 or SHIP2 selectively, or both paralogs simultaneously, small molecule inhibitors and agonists have been developed and tested in vitro and in vivo over the last decade in various disease models. These studies have shown promising results in various pre-clinical models of disease including cancer and tumor immunotherapy. In this review the potential use of SHIP inhibitors in cancer is discussed with particular attention to the molecular structure, binding site and efficacy of these SHIP inhibitors. |
| first_indexed | 2024-03-09T00:42:13Z |
| format | Article |
| id | doaj.art-f1fa61cc03094ae097714259b30307c1 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T00:42:13Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-f1fa61cc03094ae097714259b30307c12023-12-11T17:48:34ZengMDPI AGCancers2072-66942021-02-0113489010.3390/cancers13040890Targeting SHIP1 and SHIP2 in CancerChiara Pedicone0Shea T. Meyer1John D. Chisholm2William G. Kerr3Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY 13210, USAChemistry Department, Syracuse University, Syracuse, NY 13210, USAChemistry Department, Syracuse University, Syracuse, NY 13210, USADepartment of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY 13210, USAMembrane-anchored and soluble inositol phospholipid species are critical mediators of intracellular cell signaling cascades. Alterations in their normal production or degradation are implicated in the pathology of a number of disorders including cancer and pro-inflammatory conditions. The SH2-containing 5′ inositol phosphatases, SHIP1 and SHIP2, play a fundamental role in these processes by depleting PI(3,4,5)P<sub>3</sub>, but also by producing PI(3,4)P<sub>2</sub> at the inner leaflet of the plasma membrane. With the intent of targeting SHIP1 or SHIP2 selectively, or both paralogs simultaneously, small molecule inhibitors and agonists have been developed and tested in vitro and in vivo over the last decade in various disease models. These studies have shown promising results in various pre-clinical models of disease including cancer and tumor immunotherapy. In this review the potential use of SHIP inhibitors in cancer is discussed with particular attention to the molecular structure, binding site and efficacy of these SHIP inhibitors.https://www.mdpi.com/2072-6694/13/4/890SHIP1SHIP2cancerSHIPiPI3KAKT |
| spellingShingle | Chiara Pedicone Shea T. Meyer John D. Chisholm William G. Kerr Targeting SHIP1 and SHIP2 in Cancer Cancers SHIP1 SHIP2 cancer SHIPi PI3K AKT |
| title | Targeting SHIP1 and SHIP2 in Cancer |
| title_full | Targeting SHIP1 and SHIP2 in Cancer |
| title_fullStr | Targeting SHIP1 and SHIP2 in Cancer |
| title_full_unstemmed | Targeting SHIP1 and SHIP2 in Cancer |
| title_short | Targeting SHIP1 and SHIP2 in Cancer |
| title_sort | targeting ship1 and ship2 in cancer |
| topic | SHIP1 SHIP2 cancer SHIPi PI3K AKT |
| url | https://www.mdpi.com/2072-6694/13/4/890 |
| work_keys_str_mv | AT chiarapedicone targetingship1andship2incancer AT sheatmeyer targetingship1andship2incancer AT johndchisholm targetingship1andship2incancer AT williamgkerr targetingship1andship2incancer |